Lorbriqua 100mg Tablet contains lorlatinib 100mg, a prescription ALK and ROS1 tyrosine kinase inhibitor (TKI) used as targeted therapy for eligible patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). Lorlatinib is designed to inhibit abnormal ALK signaling that can drive the growth and spread of ALK-positive cancer cells. In the United States, lorlatinib is marketed as Lorbrena® by Pfizer; the brand name Lorbriqua is used in several other markets.
Lorbriqua 100mg is the established 100mg tablet strength of lorlatinib and is used according to the prescribing oncologist’s instructions. Molecular testing is required to confirm an appropriate ALK alteration before treatment.
Lorbriqua 100mg is an oral targeted cancer medicine containing lorlatinib.
Lorlatinib is a third-generation ALK inhibitor developed to inhibit ALK kinase activity, including activity associated with several ALK resistance mutations that can develop during treatment with earlier ALK inhibitors.
It is used for patients whose NSCLC contains an appropriate ALK rearrangement or alteration and whose disease meets the applicable treatment indication.
Lorbriqua/lorlatinib is primarily used for eligible patients with:
In the United States, lorlatinib is approved for first-line treatment of patients with ALK-positive metastatic NSCLC. Treatment indications can differ by country and regulatory authority.
Lorlatinib is not intended for unselected lung cancer. ALK molecular testing is essential for identifying patients who may benefit from ALK-targeted treatment.
Lorlatinib inhibits anaplastic lymphoma kinase (ALK) and interferes with signaling pathways involved in the growth and survival of ALK-positive cancer cells.
ALK-positive NSCLC can contain abnormal ALK signaling that promotes uncontrolled cell proliferation. Lorlatinib blocks this kinase activity and can inhibit signaling from both the primary oncogenic ALK alteration and several acquired resistance mutations.
Lorlatinib also has the ability to penetrate the blood-brain barrier, an important characteristic in ALK-positive NSCLC because the disease can involve the central nervous system.
The primary commercial and clinical search relationship is:
Lorbriqua 100mg → Lorlatinib 100mg → ALK Inhibitor → ALK-Positive NSCLC → Targeted Lung Cancer Therapy
Lorbriqua should only be used when the patient’s cancer has been appropriately identified as ALK-positive and the treatment is clinically indicated.
Lorbriqua and Lorbrena contain the same active ingredient, lorlatinib, but the brand name varies by market.
Lorbrena® is the brand name used by Pfizer in the United States, while Lorbriqua® is used in certain other markets. The approved indication, packaging and regulatory labeling should be checked for the country where the medicine is supplied.
Where an appropriately authorized equivalent or generic product is available, relevant searches may include:
Lorlatinib 100mg, Generic Lorlatinib 100mg, Generic Lorbriqua 100mg, Generic Lorbrena 100mg, Lorlatinib 100mg Tablet, Lorlatinib Alternative, Lorbrena Alternative.
The term generic Lorbrena or generic Lorbriqua should only be used when the specific product has the appropriate regulatory status in the target market.
The recommended lorlatinib dose for eligible adult patients is generally 100mg once daily, taken continuously, according to the applicable prescribing information.
The tablet may be taken with or without food and should be swallowed whole.
Dose interruption or reduction may be required if clinically significant adverse reactions occur or because of drug interactions.
Do not change the dose or discontinue Lorbriqua without instructions from the treating oncologist.
Lorlatinib can cause adverse reactions and requires medical monitoring.
Common or clinically important adverse effects may include:
Lorlatinib can also cause clinically significant central nervous system effects, including cognitive, mood, speech or other neuropsychiatric changes.
Serious adverse reactions can occur. Patients should promptly inform their healthcare provider about significant changes in mood, cognition, speech, coordination, blood pressure, breathing or other concerning symptoms.
Patients receiving lorlatinib may require regular monitoring of:
Lorlatinib has important interactions with CYP3A and other metabolic pathways. Patients should provide their oncologist and pharmacist with a complete list of medicines, supplements and herbal products they use.
ALK-positive NSCLC can spread to the brain. Lorlatinib has clinically important central nervous system penetration, making it particularly relevant in ALK-positive metastatic NSCLC involving or at risk of CNS disease.
However, treatment decisions for brain metastases depend on the patient’s individual clinical condition, imaging findings and previous therapy and must be made by the treating oncology team.
Lorbriqua 100mg Tablet is a prescription oncology medicine. Commercial searches commonly include Lorbriqua 100mg Tablet, Lorlatinib 100mg, Buy Lorbriqua 100mg, Buy Lorlatinib 100mg, Lorbriqua 100mg Price, Lorlatinib 100mg Price, Generic Lorlatinib 100mg, Lorbrena Alternative, ALK Inhibitor, ALK Positive Lung Cancer Treatment and related transactional terms.
Customers should obtain lorlatinib through an appropriately licensed pharmacy or authorized pharmaceutical supplier.
Availability, prescription requirements, approved indications, importation and dispensing regulations vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Lorbriqua contains lorlatinib and is used as targeted therapy for eligible patients with ALK-positive metastatic non-small cell lung cancer.
The generic name is lorlatinib.
Lorbriqua 100mg contains lorlatinib 100mg as its active pharmaceutical ingredient.
Both contain lorlatinib, but Lorbriqua and Lorbrena are brand names used in different markets. Lorbrena is the U.S. brand marketed by Pfizer.
Yes. Lorlatinib is a potent ALK tyrosine kinase inhibitor used for ALK-positive NSCLC.
Lorbriqua is used for ALK-positive non-small cell lung cancer, particularly metastatic disease under approved treatment indications.
Yes. Molecular testing is required to identify an appropriate ALK alteration before starting ALK-targeted treatment.
Lorlatinib has strong central nervous system penetration and is an important targeted therapy option for ALK-positive NSCLC with CNS involvement when clinically appropriate.
Take lorlatinib exactly as prescribed by the treating oncologist. The usual adult dose is 100mg once daily, but treatment may be modified depending on adverse reactions, interactions and individual clinical circumstances.
Common adverse effects can include increased cholesterol and triglycerides, edema, peripheral neuropathy, weight gain, fatigue and cognitive or mood-related effects.
Lorbriqua is a prescription anticancer medicine. It should be obtained only through an appropriately licensed pharmacy or authorized pharmaceutical supplier and used under specialist oncology supervision.
Yes. Healthcare professionals may monitor blood pressure, lipid levels, liver and kidney function, neurologic status and potential drug interactions during treatment.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Lorbriqua (lorlatinib) is a prescription targeted anticancer medicine requiring specialist oncology supervision. Treatment should only be started after appropriate molecular confirmation and clinical assessment. Lorlatinib can cause serious adverse reactions and clinically important drug interactions, including central nervous system effects and metabolic abnormalities. Always follow the official prescribing information for the specific product and consult a qualified oncologist before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Lorbriqua 100mg Tablet
Reviews
There are no reviews yet